Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-β

Journal of Alzheimer's Disease

Volumn 14, Issue 2, 2008, Pages 161-173

  Wang, Jun ^a,b   Hara, Hideo ^a   Makifuchi, Takao ^c   Tabira, Takeshi ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c National Saigata Medical Center   (Japan)

Author keywords

Alzheimer's disease; Immunotherapy; TAPIR like anti amyloid antibody

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G2B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3.4A10; MONOCLONAL ANTIBODY TAPIR; OLIGOMER; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL LYSATE; CONTROLLED STUDY; DENATURATION; DRUG INHIBITION; FEMALE; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; SPECTROFLUOROMETRY;

EID: 47849107601     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-14204     Document Type: Article

References (31)

1. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk and T. Yednock, Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in mouse model of Alzheimer's disease, Nat Med 6 (2000), 916-919.
2. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. Motter, M. Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert and T. Yednock, Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology, Proc Natl Acad Sci USA 100 (2003), 2023-2028.
3. R. Bullock, Future directions in the treatment of Alzheimer's disease, Expert Opin Investig Drugs 13 (2004), 303-314.
4. J.L. Cummings, Alzheimer's disease, N Engl J Med 351 (2004), 56-67.
5. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul and D.M. Holtzman, Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 98 (2001), 8850-8855.
6. D. Frenkel, M. Balass and B. Solomon, N-terminal EFRH sequence of Alzheimer's β-amyloid pepetide represents the epitope of its anti-aggregating antibodies, J Neuroimmunol 88 (1998), 85-90.
7. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, AN1792(QS-21)-201 Study Team, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
8. H. Hara, A. Monsonego, K. Yuasa, K. Adachi, X. Xiao, S. Takeda, K. Takahashi, H.L. Weiner and T. Tabira, Development of a safe oral Abeta vaccine using recombinant adeno-associated virusvector for Alzheimer's disease, J Alzheimers Dis 6 (2004), 483-488.
9. C. Hock, U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R.C. Von Rotz, G. Davey, E. Moritz and R.M. Nitsch, Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease, Nat Med 8 (2002), 1270-1275.
10. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, M.A. Wollmer, D. Umbricht, D.J. de Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos and R.M. Nitsch, Antibodies against beta-amyloid slow cognitive decline in Alzhiemer's disease, Neuron 38 (2003), 547-554.
11. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, S.D. Schmidt, M.A. Chishti, P. Home, D. Heslin, J. French, H.T. Mount, R.A. Nixon, M. Mercken, C. Bergeron, P.E. Fraser, P. St George-Hyslop and D. Westaway, A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature 408 (2000), 979-982.
12. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe and S.G. Younkin, Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease, J Neurosci 21 (2001), 372-381.
13. H.W. Klafki, M. Staufenbiel, J. Kornhuber and J. Wiltfang, Therapeutic approaches to Alzheimer's disease, Brain 129 (2006), 2840-2855.
14. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe and M.J. Rowan, Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo, Nat Med 11 (2005), 556-561.
15. E.B. Lee, L.Z. Leng, V.M. Lee and J.Q. Trojanowski, Menigoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis, FEBS Lett 579 (2005), 2564-2568.
16. S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher and K.H. Ashe, A specific amyloid-β protein assembly in brain impairs memory, Nature 440 (2006), 352-357.
17. C.L. Master, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc Natl Acad Sci USA 82 (1985), 4245-4249.
18. J. Mclaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, J.E. French, M.H. Lambermon, A.A. Darabie, M.E. Brown, C. Janus, M.A. Chishti, P. Horne, D. Westaway, P.E. Fraser, H.T. Mount, M. Przybylski and P. St George-Hyslop, Thearpeutically effective antibodies against amyloid-beta peptide target amyloid residues 4-10 and inhibit cytotoxicity and fibrillogenesis, Nat Med 8 (2002), 1263-1269.
19. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dichey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon and G.W. Arendash, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature 408 (2000), 982-985.
20. A. Mouri, Y. Noda, H. Hara, H. Mizoguchi, T. Tabira and T. Nabeshima, Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related A beta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model, FASEB J 21 (2007), 2135-2148.
21. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham and R.O. Weller, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report, Nat Med 9 (2003), 448-452.
22. R.L. Nussbaum and C.E. Ellis, Alzheimer's disease and Parkinson's disease, N Engl J Med 348 (2003), 1356-1364.
23. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank and C. Hock, Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization, Neurology 61 (2003), 46-54.
24. R.L. Patton, W.M. Kalback, C.L. Esh, T.A. Kokjohn, G.D.Van Vickle, D.C. Luehrs, Y.M. Kuo, J. Lopez, D. Brune, I. Ferrer, E. Masliah, A.J. Newel, T.G. Beach, E.M. Gastano and A.E. Roher, Amyloid-β peptide remnants in AN-1972-immunized Alzheimer's disease patients, Am J Pathol 169 (2006), 1048-1063.
25. M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P.M. Mathews and M. Jucker, Cerebral hemorrhage after passive anti-Aβ immunotherapy, Science 298 (2002), 1379.
26. M.M. Racke, L.I. Boone, D.L. Hepburn, M. Parsadainian, M.T. Bryan, D.K. Ness, K.S. Piroozi, W.H. Jordan, D.D. Brown, W.P. Hoffman, D.M. Holtzman, K.R. Bales, B.D. Gitter, P.C. May, S.M. Paul and R.B. DeMattos, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β, J Neurosci 25 (2005), 629-636.
27. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games and P. Seubert, Immunization with amyloid-β attenuates Alzheimer-disease like pathology in the PDAPP mouse, Nature 400 (1999), 173-177.
28. D.J. Selkoe and D. Schenk, Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics, Annu Rev Pharmacol Toxicol 43 (2003), 545-584.
29. B. Solomon, R. Koppel, E. Hanan and T. Katzav, Monoclonal antibodies inhibit in vitro fibrillar aggregation of Alzheimer β-amyloid peptide, Proc Natl Acad Sci USA 93 (1996), 452-455.
30. B. Solomon, R. Koppel, D. Frankel and E. Hanan-Aharon, Disaggregation of Alzheimer β-amyloid by site-directed mAb, Proc Natl Acad Sci USA 94 (1997), 4109-4112.
31. H.L. Weiner and D. Frenkel, Immunology and immunotherapy of Alzheimer's disease, Nat Rev Immunol 6 (2006), 404-416.